proportion of patients increasing infliximab dose over time according to its use as a first, second, or third line biologic agent
| Follow-up time | First line (N=373) | Second line (N=210) | Third line (N=133) |
|---|---|---|---|
| 12 months, % | 21 | 31 | 30 |
| 24 months, % | 35 | 46 | 58 |
| 36 months, % | 49 | 62 | 81 |